Current development of cabazitaxel drug delivery systems
WIREs Nanomedicine and Nanobiotechnology · 2023-03 · 15 (2)
DOI: 10.1002/wnan.1854 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift WIREs Nanomedicine and Nanobiotechnology, online erschienen am 25.09.2022. Verfasst von Boyang Sun und 2 weiteren Autor:innen. Beteiligte Einrichtung: School of Chemical Engineering and Technology, Key Laboratory of Systems Bioengineering (Ministry of Education), Frontiers Science Center for Synthet…. Hauptthemen laut MEDLINE: Antineoplastic Agents. Die Arbeit wurde bisher 39-mal zitiert (Crossref) und nennt 159 Literaturangaben. Gefördert von: National Natural Science Foundation of China, National Key Research and Development Program of China.
Abstract (Originalsprache)
The second‐generation taxane cabazitaxel has been clinically approved for the treatment of metastatic castration‐resistant prostate cancer after docetaxel failure. Compared with the first‐generation taxanes paclitaxel and docetaxel, cabazitaxel has potent anticancer activity and is less prone to drug resistance due to its lower affinity for the P‐gp efflux pump. The relatively high hydrophobicity of cabazitaxel and the poor aqueous colloidal stability of the commercial formulation, following its preparation for injection, presents opportunities for new cabazitaxel formulations with improved features. This review provides an overview of cabazitaxel drug formulations and hydrophobic taxane drug delivery systems in general, and particularly focuses on emerging cabazitaxel delivery systems discovered in the past 5 years. This article is categorized under: Therapeutic Approaches and Drug Discovery > Nanomedicine for Oncologic Disease Therapeutic Approaches and Drug Discovery > Emerging Technologies
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- School of Chemical Engineering and Technology, Key Laboratory of Systems Bioengineering (Ministry of Education), Frontiers Science Center for Synthetic Biology (Ministry of Education), Tianjin University, Tianjin, China.
- Department of Biomedical Engineering, University at Buffalo, State University of New York, Buffalo, New York, USA.
ORCID-Profile: Yumiao Zhang
Förderung
- National Natural Science Foundation of China
- National Key Research and Development Program of China
Zitieren
APA
Sun, B., Lovell, J. F., & Zhang, Y. (2023). Current development of cabazitaxel drug delivery systems. WIREs Nanomedicine and Nanobiotechnology, 15(2). https://doi.org/10.1002/wnan.1854
Vancouver
Sun B, Lovell JF, Zhang Y. Current development of cabazitaxel drug delivery systems. WIREs Nanomedicine and Nanobiotechnology. 2023;15(2). doi:10.1002/wnan.1854
BibTeX
@article{Sun2023,
author = {Sun, Boyang and Lovell, Jonathan F and Zhang, Yumiao},
title = {Current development of cabazitaxel drug delivery systems},
journal = {WIREs Nanomedicine and Nanobiotechnology},
year = {2023},
volume = {15},
number = {2},
doi = {10.1002/wnan.1854}
}
EUVIMED